Abstract
The mitochondrion provides the stage for the interplay of molecular interactions that regulate apoptosis via the intrinsic pathway. The release of apoptogenic factors from this compartment constitutes a critical juncture in this apoptotic pathway. Regulation of the integrity of the outer mitochondrial membrane (OMM) is the task of the Bcl-2 family of proteins. A network of interactions between the various subgroups of the family decides the apoptotic fate of a cell and, as such, an imbalance within this network can lead to a variety of disease states. In particular, over-expression of pro-survival Bcl-2 family proteins is a hallmark of many cancers. Here we discuss recent advances in targeting the Bcl-2 family with both peptides and small molecules.
Current Pharmaceutical Design
Title: Bcl-2 Family Proteins as Therapeutic Targets
Volume: 16 Issue: 28
Author(s): Peter E. Czabotar and Guillaume Lessene
Affiliation:
Abstract: The mitochondrion provides the stage for the interplay of molecular interactions that regulate apoptosis via the intrinsic pathway. The release of apoptogenic factors from this compartment constitutes a critical juncture in this apoptotic pathway. Regulation of the integrity of the outer mitochondrial membrane (OMM) is the task of the Bcl-2 family of proteins. A network of interactions between the various subgroups of the family decides the apoptotic fate of a cell and, as such, an imbalance within this network can lead to a variety of disease states. In particular, over-expression of pro-survival Bcl-2 family proteins is a hallmark of many cancers. Here we discuss recent advances in targeting the Bcl-2 family with both peptides and small molecules.
Export Options
About this article
Cite this article as:
E. Czabotar Peter and Lessene Guillaume, Bcl-2 Family Proteins as Therapeutic Targets, Current Pharmaceutical Design 2010; 16 (28) . https://dx.doi.org/10.2174/138161210793292429
DOI https://dx.doi.org/10.2174/138161210793292429 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications
Current Neuropharmacology Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine Suppression of HIV Replication In Vitro by CpG and CpG Conjugated to the Non Toxic B Subunit of Cholera Toxin
Current HIV Research Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review
Mini-Reviews in Medicinal Chemistry Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas
Anti-Cancer Agents in Medicinal Chemistry Small Molecules Targeting p53 to Improve Antitumor Therapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Oncolytic viruses]
Current Pharmaceutical Biotechnology Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design